Glycosmedia Weekly Diabetes News - 12/06/2019

The Utility of Lower Glycemic Targets for Treating Gestational Diabetes: A Retrospective Study

Lower glycemic targets did not produce large reductions in fetal overgrowth, but they were associated with a higher rate of inductions. As there were no observed differences in maternal or neonatal outcomes otherwise, aiming for lower glycemic targets in GDM is likely not cost-effective (Journal of Diabetes Research)

Fournier’s gangrene and sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of randomized controlled trials

Data from RCTs do not show an increased risk of FG among patients, unlike pharmacovigilance reports, but the number of recorded cases is small (Diabetes, Obesity and Metabolism)

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?

The addition of empagliflozin to anti‐hyperglycemic regimens of patients with type 2 diabetes and CV disease consistently reduced their risks of adverse CV outcomes and mortality irrespective of baseline use of metformin, sulfonylurea, or insulin. For CKD progression, there may be a larger benefit from empagliflozin in those patients who are not using metformin (Diabetes, Obesity and Metabolism)

Persistent whole day meal effects of three dipeptidyl peptidase‐4 inhibitors on glycemia and hormonal responses in metformin‐treated type 2 diabetes

DPP‐4 inhibition has persistent daytime effects on glucose, islet and incretin hormones with no difference between three different DPP‐4 inhibitors (Diabetes, Obesity and Metabolism)

Impact of chronic kidney disease definition on assessment of its incidence and risk factors in patients with newly diagnosed type 1 and type 2 diabetes in the UK

A cohort study using primary care data from the United Kingdom (Primary Care Diabetes)